Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
January 6, 2016 9:26 AM ESTRoth Capital reiterated a Buy rating and $15.00 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) following the company's reported three-month data from its double-blind, placebo-controlled Phase 2 trial in liver cirrhosis patients. The data indicated that there is a significant functional benefit for severe cirrhotic patients treated with emricasan.
Analyst Elemer Piros commented,... More
Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%
January 5, 2016 4:38 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ET
January 5, 2016 4:11 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET
... More